Ascendis Pharma A/S ASND
259.85 USD +3.03 (+1.18%)
At closeNov 10, 2026, 7:28 AM EST
263.97 +4.12 +1.59%
Pre-market · Nov 10, 7:28 AM ET
252.82 Day range 260.66
188.07 52-week range 282.15
- YTD
- +21.86%
- 1 year
- +31.41%
News
benzinga.com Ascendis Pharma Says COMP Of EMA Adopts Positive Opinion Recommending Maintenance Of Orphan Medicinal Product Designation For Once-Weekly TransCon CNP As Treatment For Achondroplasia In Children Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending…
benzinga.com Ascendis Pharma Reports Sustained Kidney Function Improvements Over 5-Years With TransCon PTH In Adults With Hypoparathyroidism Ascendis Pharma A/S (NASDAQ:ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with hypoparathyroidism treated with…
benzinga.com Ascendis Pharma Receives Positive Opinion From Committee For Medicinal Products For Human Use Of European Medicines Agency For Marketing Authorization Of TransCon CNP In EU To Treat Achondroplasia Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending…
benzinga.com Here’s How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 13.7% on an annualized basis producing an average annual return of 27.5%. Currently, Ascendis Pharma has a market…
benzinga.com Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 14.04% on an annualized basis producing an average annual return of 27.55%. Currently, Ascendis Pharma has a market…
benzinga.com Why Is Ascendis Pharma Stock Trading Lower on Tuesday? Ascendis Pharma shares dip as it reclaims TransCon technology rights from Novo Nordisk and initiates a $400 million share repurchase program.
benzinga.com 10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi pipeline outages, pressuring stocks ahead of the Fed.
benzinga.com This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday Analysts downgraded Banco Santander Brasil, Ribbon Communications, Cellectis, Scholar Rock, with mixed price-target changes.
benzinga.com Raymond James Downgrades Ascendis Pharma to Outperform, Maintains Price Target to $287 Raymond James analyst Martin Auster downgrades Ascendis Pharma (NASDAQ:ASND) from Strong Buy to Outperform and maintains the price target from $287 to $287.
benzinga.com Ascendis Pharma Authorizes Up To $400M Share Repurchase Program Ascendis Pharma A/S (NASDAQ:ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of the Company’s ordinary shares (the Share Repurchase…
benzinga.com Ascendis Pharma Regains Exclusive Rights To TransCon Tech Products After Ending Novo Nordisk Collaboration; Ascendis To Initiate Multiple Programs In Metabolic And Cardiovascular Diseases, Including Obesity - All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis- Ascendis to initiate multiple…- benzinga.com $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 16.08% on an annualized basis producing an average annual return of 29.64%. Currently, Ascendis Pharma has a market…
benzinga.com Ascendis Pharma Says Growth Drug Shows Benefits in Infants Ascendis Pharma released positive 52-week data for TransCon CNP in infants with achondroplasia from its Phase 2 reACHin trial.- benzinga.com Ascendis Announces Week 52 Data From Open-Label Sentinel Cohort Portion Of reACHin Trial Showing Treatment With Once-Weekly TransCon CNP Provided Stabilization Or Improvement In Foramen Magnum Stenosis And Linear Growth Benefits In Infants With Achondroplasia – Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with TransCon CNP treatment – Treatment with TransCon CNP increased linear growth in the sentinel cohort,…
benzinga.com Reported Earlier, Ascendis Pharma To Present New Infant Achondroplasia Trial Data At ESPE 2026 Ascendis Pharma A/S (NASDAQ:ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026, the annual congress of the European Society for…- benzinga.com Oppenheimer Maintains Outperform on Ascendis Pharma, Raises Price Target to $312 Oppenheimer analyst Leland Gershell maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $304 to $312.
benzinga.com Morgan Stanley Maintains Overweight on Ascendis Pharma, Lowers Price Target to $273 Morgan Stanley analyst Maxwell Skor maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $275 to $273.
benzinga.com Wedbush Reiterates Outperform on Ascendis Pharma, Maintains $327 Price Target Wedbush analyst Yun Zhong reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and maintains $327 price target.
benzinga.com Oil Jumps Near $90 On Iran Risk, California Utilities Crater: Stock Market Today Brent climbed after new U.S.-Iran strikes, pushing the 10-year yield to a 19-month high; Edison and PG&E collapsed on a wildfire bill.- benzinga.com B of A Securities Maintains Buy on Ascendis Pharma, Lowers Price Target to $304 B of A Securities analyst Tazeen Ahmad maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $306 to $304.
- benzinga.com Jefferies Maintains Buy on Ascendis Pharma, Lowers Price Target to $330 Jefferies analyst Kelly Shi maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $333 to $330.
- benzinga.com Stifel Maintains Buy on Ascendis Pharma, Lowers Price Target to $326 Stifel analyst Alex Thompson maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $328 to $326.
- benzinga.com Crude Oil Gains Over 2%; US Dallas Fed Manufacturing Index Surges In August U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Monday.The Dow traded down 0.64% to 53,219.55 while the NASDAQ dipped 0.40% to 26,296.20.…
- benzinga.com HC Wainwright & Co. Maintains Buy on Ascendis Pharma, Lowers Price Target to $344 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $345 to $344.
benzinga.com Ascendis Pharma, Science Applications International And Other Big Stocks Moving Higher On Monday U.S. stocks were lower, with the Dow Jones index falling around 400 points on Monday. Shares of Ascendis Pharma A/S (NASDAQ:ASND) rose sharply on Monday. On Sunday, BioMarin Pharmaceutical Inc.…
benzinga.com Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes BioMarin Pharmaceutical and Ascendis Pharma settled global patent disputes over Yuviwel, granting BioMarin significant royalty payments.- benzinga.com Ascendis, Biomarin Enter Binding Global Settlement And License Agreement Resolving All Litigation, Granting Ascendis Worldwide Rights To Develop, Commercialize Navepegritide Products, With Royalty Payments On YUVIWEL Sales Through 2030 Ascendis Pharma A/S (NASDAQ:ASND) today announced it has entered into a binding term sheet for a global settlement and license agreement with BioMarin Pharmaceutical Inc. ("BioMarin") related to the…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Ascendis Pharma, Maintains $345 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Ascendis Pharma (NASDAQ:ASND) with a Buy and maintains $345 price target.
benzinga.com This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday Analysts initiate coverage and change ratings on top stocks like ASND, DOCN, ODTX, MT, and NVCT. See their price targets and views on these stocks.- benzinga.com HC Wainwright & Co. Initiates Coverage On Ascendis Pharma with Buy Rating, Announces Price Target of $345 HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and announces Price Target of $345.
- benzinga.com If You Invested $1000 In Ascendis Pharma Stock 10 Years Ago, You Would Have This Much Today Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 16.69% on an annualized basis producing an average annual return of 30.07%. Currently, Ascendis Pharma has a market…
- benzinga.com BMO Capital Initiates Coverage On Ascendis Pharma with Outperform Rating, Announces Price Target of $319 BMO Capital analyst David Lebowitz initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Outperform rating and announces Price Target of $319.
- benzinga.com TD Cowen Maintains Buy on Ascendis Pharma, Raises Price Target to $341 TD Cowen analyst Yaron Werber maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $325 to $341.
- benzinga.com RBC Capital Maintains Outperform on Ascendis Pharma, Raises Price Target to $290 RBC Capital analyst Luca Issi maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $280 to $290.
- benzinga.com Barclays Maintains Overweight on Ascendis Pharma, Lowers Price Target to $329 Barclays analyst Eliana Merle maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $345 to $329.
benzinga.com Full Transcript: Ascendis Pharma Q2 2026 Earnings Call Ascendis Pharma (NASDAQ:ASND) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide…- benzinga.com Ascendis Pharma Q2 Adj. EPS $1.05 Beats $0.78 Estimate, Sales $394.437M Beat $353.800M Estimate Ascendis Pharma (NASDAQ:ASND) reported quarterly earnings of $1.05 per share which beat the analyst consensus estimate of $0.78 by 34.62 percent. This is a 212.9 percent increase over losses of…
benzinga.com Here's How Much $100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth Today Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 5 years by 5.62% on an annualized basis producing an average annual return of 17.21%. Currently, Ascendis Pharma has a market…- benzinga.com Morgan Stanley Maintains Overweight on Ascendis Pharma, Raises Price Target to $275 Morgan Stanley analyst Maxwell Skor maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $256 to $275.
- benzinga.com RBC Capital Maintains Outperform on Ascendis Pharma, Raises Price Target to $280 RBC Capital analyst Luca Issi maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $275 to $280.
- benzinga.com Ascendis Pharma Announces It Has Been Added To Multiple Russell U.S. Indexes, Including the Russell 3000, Russell 1000, Russell 2500 And Russell Midcap Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Company has been added to the broad-market Russell 3000® Index, the large-cap Russell 1000® Index, the small-to-mid-cap Russell 2500® Index,…
- benzinga.com Reported Saturday, Ascendis Pharma's TransCon PTH Achieves 86% Response Rate And 100% Independence From Active Vitamin D Through Week 182 In Phase 3 PaTHway Trial Adults With Hypoparathyroidism Multi-organ system and quality-of-life benefits sustained through three and a half years 86% response rate for the multi-component endpoint89% of patients completed the three-and-a-half-year trial
benzinga.com Why Is Ascendis Pharma Stock Gaining Friday? Ascendis Pharma (ASND) stock rises after releasing impressive 5-year Phase 2 data for its hypoparathyroidism drug.- benzinga.com Ascendis Pharma A/S Data From Phase 2 PaTH Forward Study Of TransCon PTH Demonstrates Sustained Efficacy, Safety In Participants With Hypoparathyroidism Ascendis Pharma A/S (NASDAQ:ASND) today announced 5-year (Week 266) data from its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated…
- benzinga.com Citigroup Initiates Coverage On Ascendis Pharma with Buy Rating, Announces Price Target of $355 Citigroup analyst Eric Joseph initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and announces Price Target of $355.
- benzinga.com Evercore ISI Group Maintains Outperform on Ascendis Pharma, Raises Price Target to $329 Evercore ISI Group analyst Josh Schimmer maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $324 to $329.
- benzinga.com Barclays Maintains Overweight on Ascendis Pharma, Raises Price Target to $345 Barclays analyst Eliana Merle maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $342 to $345.
benzinga.com Wells Fargo Maintains Overweight on Ascendis Pharma, Lowers Price Target to $326 Wells Fargo analyst Derek Archila maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $330 to $326.- benzinga.com Ascendis Pharma Q1 Adj. EPS $0.32 Beats $0.21 Estimate, Sales $288.770M Miss $318.050M Estimate Ascendis Pharma (NASDAQ:ASND) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.21 by 52.38 percent. This is a 119.28 percent increase over losses of…
benzinga.com Earnings Scheduled For February 11, 2026